Free tool
FAERS Monitor: Eovist
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022090 or its brand name (Eovist, Gadoxetate Disodium). Reports on generic versions are filed under their own applications.
Reports
441
Serious
244
55% of reports
Hospitalization
30
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- rash160
- pain155
- paraesthesia154
- arthralgia153
- burning sensation153
- hypoaesthesia153
- muscle spasms153
- gadolinium deposition disease152
- injury152
- asthenia150
- confusional state150
- fatigue150
- inflammation150
- mass147
- anxiety80
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 5 |
| 2009 | 16 |
| 2010 | 40 |
| 2011 | 47 |
| 2012 | 23 |
| 2013 | 19 |
| 2014 | 20 |
| 2015 | 14 |
| 2016 | 18 |
| 2017 | 14 |
| 2018 | 14 |
| 2019 | 165 |
| 2020 | 7 |
| 2021 | 8 |
| 2022 | 5 |
| 2023 | 10 |
| 2024 | 8 |
| 2025 | 4 |
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,718 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| gadolinium deposition diseaseSignal | 152 | 18096.3 | 15394.7 | 1,981,315 |
| massSignal | 147 | 506.9 | 443.7 | 72,988 |
| inflammationSignal | 150 | 139.0 | 122.0 | 20,408 |
| burning sensationSignal | 153 | 104.3 | 91.7 | 15,568 |
| injurySignal | 152 | 103.3 | 90.8 | 15,321 |
| hypoaesthesiaSignal | 153 | 48.8 | 42.9 | 7,159 |
| paraesthesiaSignal | 154 | 46.7 | 41.1 | 6,891 |
| confusional stateSignal | 150 | 44.3 | 38.9 | 6,350 |
| muscle spasmsSignal | 153 | 39.8 | 35.0 | 5,793 |
| astheniaSignal | 150 | 19.0 | 16.7 | 2,590 |
| arthralgiaSignal | 153 | 17.6 | 15.4 | 2,419 |
| rashSignal | 160 | 17.5 | 15.5 | 2,526 |
| anxietySignal | 80 | 13.4 | 11.0 | 919 |
| painSignal | 155 | 12.0 | 10.6 | 1,604 |
| fatigueSignal | 150 | 9.2 | 8.1 | 1,128 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.